Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed 015K-CL-RAJ1 Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: July 9, 2012
Last updated: July 25, 2013
Last verified: July 2013

The purpose of this study is to evaluate the safety and efficacy of long-term administration of ASP015K in patients who completed the 15K-CL-RAJ1 study.

Condition Intervention Phase
Arthritis, Rheumatoid
Drug: ASP015K
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Phase IIb Extension Study of ASP015K - Open-Label Extension Study in RA Patients Who Have Completed Phase IIb Study of ASP015K -

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and labo-tests [ Time Frame: To the end of the study (up to 132 weeks) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response [ Time Frame: At each study visit (up to 132 weeks) ] [ Designated as safety issue: No ]
  • Percentage of Subjects achieving ACR 50 response [ Time Frame: At each study visit (up to 132 weeks) ] [ Designated as safety issue: No ]
  • Percentage of Subjects achieving ACR 70 response [ Time Frame: At each study visit (up to 132 weeks) ] [ Designated as safety issue: No ]
  • Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) [ Time Frame: At each study visit (up to 132 weeks) ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: July 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASP015K group Drug: ASP015K

Detailed Description:

This study is an extension of study RAJ1 conducted as an open-label multicenter study in RA patients who completed study RAJ1.

Patients will receive oral ASP015K once daily (QD) after breakfast. The ASP015K dose can be increased later if the subjects have no safety problems but show lack of efficacy. The dose level will be reconsidered after the results of the dose-setting study (study RAJ1) have been obtained.

Because this study will end at the point in time where the Phase III study begins, the duration of treatment with the study drug will differ depending upon the subject (planned maximum duration of treatment: 132 weeks).


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has completed treatment with the study drug in study RAJ1as specified in the protocol
  • The subject himself/herself wishes to continue taking the study drug, and the investigator or sub-investigator deems continued administration to be necessary or appropriate

Exclusion Criteria:

  • Subject has developed an adverse reaction to the study drug in study RAJ1 and the risks of continuing treatment with this drug are expected to outweigh the benefits
  • There were abnormal findings in the x-ray taken at Week 0, and an acute or chronic infection, tuberculosis infection, or malignancy is suspected
  • Hepatitis B virus or hepatitis C virus carrier or has a history of a positive test for human immunodeficiency virus (HIV) infection
  • Subject has concurrent autoimmune disease (except Sjogren's syndrome) other than RA or a history of it
  • Subject has a clinically significant infection or disease (requiring hospitalization or parenteral therapy)
  • Subject has taken one of the following drugs between the end of the assessments at Week 12 of study RAJ1 and the start of treatment with the study drug in this Extension Study.

    • Biologic DMARD (biologic for the treatment of RA): Etanercept, adalimumab, golimumab, infliximab, tocilizumab, abatacept, rituximab
    • Non-biologic DMARD: Methotrexate, salazosulfapyridine, gold, D-penicillamine, leflunomide, lobenzarit, actarit, tacrolimus, mizorinbine, bucillamine (However, topical drugs other than those for the treatment of RA may be used.)
    • Other drugs used in the treatment of RA: Cyclosporine
  • Subject has received plasma exchange therapy between the end of the assessments at Week 12 of study RAJ1 and the start of treatment with the study drug in this Extension Study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01638013

Chubu, Japan
Chugoku, Japan
Hokkaido, Japan
Kansai, Japan
Kantou, Japan
Kyushu, Japan
Touhoko, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Inc
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc Identifier: NCT01638013     History of Changes
Other Study ID Numbers: 015K-CL-RAJ2
Study First Received: July 9, 2012
Last Updated: July 25, 2013
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Astellas Pharma Inc:
Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on November 24, 2014